HER-2 Overexpression in Breast Cancer: Primary vs. Metastatic Sites
Author Information
Author(s): Zidan J, Dashkovsky I, Stayerman C, Basher W, Cozacov C, Hadary A
Primary Institution: Sieff Government Hospital, Safed, Israel
Hypothesis
This study aims to evaluate HER-2 overexpression in primary and metastatic breast cancer and its effect on treatment decisions.
Conclusion
The study found a 14% discordance in HER-2 overexpression between primary and metastatic breast cancer, which can impact treatment decisions.
Supporting Evidence
- HER-2 overexpression was found in 24% of primary breast cancer tissues.
- Concordance between primary and metastatic HER-2 status was observed in 86% of patients.
- Discordance in HER-2 overexpression was noted in 14% of cases.
Takeaway
Sometimes, the cancer in the original tumor and the cancer that spreads can be different, which is important to know for choosing the right medicine.
Methodology
Biopsies from primary breast cancer and corresponding metastases were studied using immunohistochemistry and fluorescence in situ hybridization.
Potential Biases
Potential bias may arise from the selection of patients and the retrospective analysis of some cases.
Limitations
The study is limited by the small sample size and the retrospective nature of some data.
Participant Demographics
Median age was 56 years, with 98% female and 2% male participants.
Statistical Information
P-Value
0.07
Confidence Interval
95% CI: 77–95
Statistical Significance
p=0.07
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website